Background: Antibody reactivity to microbial antigens correlates with distinct Crohn's disease (CD) phenotypes such as fistulizing or fibrostenosing disease. We examined the association between anti-CBir1 and clinical phenotypes and NOD2 variants in a large cohort of adult CD patients.

Methods: Sera and genomic DNA were collected from 731 patients with CD and tested for immune responses to I2, CBir1, oligomannan, and outer membrane porin C (OmpC) and the 3 most common CD-associated NOD2 variants.

Results: Anti-CBir1 reactivity was significantly associated with fibrostenosis (FS), internal penetrating (IP) disease phenotypes, small bowel (SB) involvement, and SB surgery but negatively associated with ulcerative colitis (UC)-like CD. Multivariate logistic regression analysis showed that anti-CBir1 was independently associated with FS and UC-like CD irrespective of the antibody reactivity to I2, oligomannan, or OmpC, but not with SB involvement or SB surgery. The magnitude of anti-CBir1 reactivity, when added to the quantitative response toward the other 3 CD-associated antigens, enhances the discrimination of FS, IP, UC-like CD, and SB involvement, but not SB surgery. Finally, although the frequency of anti-CBir1 was similar in patients with none versus at least 1 NOD2 variant, the quantitative response to CBir1 flagellin was significantly higher in patients with CD carrying at least 1 NOD2 variant versus those carrying no variants (median anti-CBir1 titer 33.39 versus 28.36, respectively; P = 0.01).

Conclusions: Anti-CBir1 serum reactivity in CD patients is independently associated with FS and complicated SB CD. Quantitative, but not qualitative, response to CBir1 is also significantly associated with the CD-associated NOD2 variants.

(Inflamm Bowel Dis 2007)

REFERENCES

1 Podolsky DK. Inflammatory bowel disease [see Comment]. N Engl J Med. 2002; 347: 417–429.
10.1056/NEJMra020831
CAS PubMed Web of Science® Google Scholar
2 Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005; 128: 2020–2028.
10.1053/j.gastro.2005.03.046
CAS PubMed Web of Science® Google Scholar
3 Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease [see Comment]. Gastroenterology. 2004; 126: 414–424.
10.1053/j.gastro.2003.11.015
CAS PubMed Web of Science® Google Scholar
4 Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004; 99: 2376–2384.
10.1111/j.1572-0241.2004.40417.x
PubMed Web of Science® Google Scholar
5 Dubinsky MC, Lin YC, Dutridge D, et al., Western Regional Pediatric IBDRA. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006; 101: 360–367.
10.1111/j.1572-0241.2006.00456.x
PubMed Web of Science® Google Scholar
6 Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002; 123: 679–688.
10.1053/gast.2002.35393
CAS PubMed Web of Science® Google Scholar
7 Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease [see Comment]. Gastroenterology. 2002; 122: 854–866 [erratum, Gastroenterology, 2003;125:281].
10.1053/gast.2002.32413
CAS PubMed Web of Science® Google Scholar
8 Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease [see comment]. Gastroenterology. 2002; 122: 867–874.
10.1053/gast.2002.32415
CAS PubMed Web of Science® Google Scholar
9 Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet. 2002; 359: 1661–1665.
10.1016/S0140-6736(02)08590-2
CAS PubMed Web of Science® Google Scholar
10 Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002; 70: 845–857.
10.1086/339432
CAS PubMed Web of Science® Google Scholar
11 Mei L, Targan SR, Landers CJ, et al. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology. 2006; 130: 1078–1085.
10.1053/j.gastro.2006.02.013
CAS PubMed Web of Science® Google Scholar
12 Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004; 113: 1296–1306.
10.1172/JCI200420295
CAS PubMed Web of Science® Google Scholar
13 Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup [see Comment]. Gastroenterology. 1996; 110: 1810–1819.
10.1053/gast.1996.v110.pm8964407
CAS PubMed Web of Science® Google Scholar
14 Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000; 47: 487–496.
10.1136/gut.47.4.487
CAS PubMed Web of Science® Google Scholar
15 Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations [see Comment]. Lancet. 2001; 357: 1925–1928 [erratum, Lancet, 2002;360:806].
10.1016/S0140-6736(00)05063-7
CAS PubMed Web of Science® Google Scholar
16 Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease [see Comment]. Nature. 2001; 411: 599–603.
10.1038/35079107
CAS PubMed Web of Science® Google Scholar
17 Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease [see Comment]. Nature. 2001; 411: 603–606.
10.1038/35079114
CAS PubMed Web of Science® Google Scholar
18 Kutyavin IV, Afonina IA, Mills A, et al. 3′-Minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res. 2000; 28: 655–661.
10.1093/nar/28.2.655
CAS PubMed Web of Science® Google Scholar
19 Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002; 123: 689–699.
10.1053/gast.2002.35379
CAS PubMed Web of Science® Google Scholar
20 Brant SR, Picco MF, Achkar JP, et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003; 9: 281–289.
10.1097/00054725-200309000-00001
PubMed Web of Science® Google Scholar
21 Smith BR, Arnott ID, Drummond HE, Nimmo ER, Satsangi J. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm Bowel Dis. 2004; 10: 521–528.
10.1097/00054725-200409000-00005
PubMed Web of Science® Google Scholar
22 Devlin S, Ippoliti A, Mei L, et al. NOD2/CARD15 variants are significantly associated with sero-reactivity to microbial antigens in patients with Crohn's disease and their unaffected relatives. Gastroenterology. 2007 (in press).
10.1053/j.gastro.2006.11.013
PubMed Web of Science® Google Scholar
23 Ramos HC, Rumbo M, Sirard JC. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. Trends Microbiol. 2004; 12: 509–517.
10.1016/j.tim.2004.09.002
CAS PubMed Web of Science® Google Scholar
24 Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001; 410: 1099–1103.
10.1038/35074106
CAS PubMed Web of Science® Google Scholar
25 Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol. 2003; 170: 5165–5175.
10.4049/jimmunol.170.10.5165
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume13, Issue5

May 2007

Pages 524-530

Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations

Abstract

REFERENCES

Citing Literature

References

Related

Information